11:41 AM EST - ProMetic Life Sciences Inc. : Announced today new data from its plasma-derived plasminogen replacement therapy Phase I clinical trial for the treatment of Congenital Plasminogen Deficiency. The results from the two cohorts of patients enrolled in the Phase I trial confirm that ProMetic's plasminogen replacement therapy is safe, well tolerated and without any related serious adverse events. Moreover, there were no plasminogen antibodies detected and the results confirm the established therapeutic dose of 6 mg/kg. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.09 at $3.11.
